Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase

Ol'ga Yur'evna Vinogradova; Виноградова Ольга Юрьевна; Anna Grigor'evna Turkina; Туркина Анна Григорьевна; Aleksandra Valer'evna Vorontsova; Воронцова Александра Валерьевна; Ekaterina Yur'evna Chelysheva; Челышева Екатерина Юрьевна; Galina Anatol'evna Gusarova; Гусарова Галина Анатольевна; S V Kuznetsov; Кузнецов С В; Svetlana Rudol'fovna Goryacheva; Горячева Светлана Рудольфовна; Manana Aleksandrovna Sokolova; Соколова Манана Александровна; Evgeniy Mikhaylovich Abakumov; Абакумов Евгений Михайлович; Ol'ga Veniaminovna Stakhina; Стахина Ольга Вениаминовна; Elena Vasil'evna Domracheva; Домрачева Елена Васильевна; Andrey Vital'evich Misyurin; Мисюрин Андрей Витальевич; Nina Dmitrievna Khoroshko; Хорошко Нина Дмитриевна; O Yu Vinogradova; Vinogradova O Yu; A G Turkina; Turkina A G; A V Vorontsova; Vorontsova A V; E Yu Chelysheva; Chelysheva E Yu; G A Gusarova; Gusarova G A; S V Kuznetsov; Kuznetsov S V; S R Goryacheva; Goryacheva S R; M A Sokolova; Sokolova M A; E M Abakumov; Abakumov E M; O V Stakhina; Stakhina O V; E V Domracheva; Domracheva E V; A V Misyurin; Misyurin A V; N D Khoroshko; Khoroshko N D

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase

作者: Vinogradova O.Y.¹, Turkina A.G.¹, Vorontsova A.V.¹, Chelysheva E.Y.¹, Gusarova G.A.¹, Kuznetsov SV¹, Goryacheva S.R.¹, Sokolova M.A.¹, Abakumov E.M.¹, Stakhina O.V.¹, Domracheva E.V.¹, Misyurin A.V.¹, Khoroshko N.D.¹, Vinogradova OY.¹, Turkina AG¹, Vorontsova AV¹, Chelysheva EY.¹, Gusarova GA¹, Kuznetsov SV¹, Goryacheva SR¹, Sokolova MA¹, Abakumov EM¹, Stakhina OV¹, Domracheva EV¹, Misyurin AV¹, Khoroshko ND¹
隶属关系:
1. ГУ Гематологический научный центр РАМН
期: 卷 81, 编号 7 (2009)
页面: 41-46
栏目: Editorial
URL: https://journal-vniispk.ru/0040-3660/article/view/30380
ID: 30380

如何引用文章

详细

Aim. To analyse resistance to imatinib therapy, efficacy and safety of dasatinib.
Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.
Results. Lethal outcomes during dasatinib treatment were absent. To September 2008, 16(89%) patients were alive, 2(11%) patients died of the disease progression after dasatinib discontinuation. A complete clinicohematological response was observed in all the patients. Major cytogenetic, complete cytogenetic, major molecular, complete molecular responses were achieved in 12(67%), 10(55%), 7(39%) and 5(28%) patients, respectively. Hematological and non-hematological toxicity occurred in 9(50%) patients. Now 12(67%) patients continue dasatinib treatment, in 6(33%) patients the drug was discontinued.
Conclusion. The results from trials in Russian Hematological Research Center are the same as in the international study. Dasatinib is effective and well tolerated therapeutic option for imatinib-resistant patients with a chronic phase of CML.

关键词

chronic myeloid leukemia, tyrosinkinase inhibitors, dasatinib, Ph-positive clone, BCR-ABL gene

参考

Kantarjian H., Pasquini R., Hamerschlak N. et al. Dasatinib or high-dose imatinib for with chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109 (12): 5143-5150.
Stephen G., O'Brien S. G., Guilhot F. et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate, of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with Imatinib. Blood 2008; 112 (11): 76, abstr. 186.
Shah N. P. DASATINIB. Drugs of Today 2007; 43 (1): 5-12.
Shah N. P., Tran C., Lee F. Y. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
Donato N. Activity of a novel turosine kinase inhibitor BMS-354825 on STI571 sensitive and resistant CML cells. Bristol-Myers Squibb, Jan 02, 2003. BMS Document Control N. 930003220.
O'Harre T., Walters D. K., Stoffregen E. P. et al. Com-bind Abl inhibition therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 2005; 11: 6987-6993.
Tokarski J., Newitt J., Lee F. The crustal structure of ABL kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood 2004; 104: 160a.
Sokal J. E., Cox E. B., Baccarani M. et al. Blood 1984; 63; 789-799.
Туркина А. Г. Клиническое значение молекулярно-генетических и иммунофенотипических характеристик хронического миелолейкоза: Автореф. дис. ... д-ра мед. наук. 1998.
Baccarani M. et al. Haematologica 2008; 93: 161-169.

补充文件

附件文件

动作

1. JATS XML

下载

用户名
密码
记住我

忘记您的密码?	注册

用户名
密码
记住我

忘记您的密码?	注册

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase

全文:

详细

关键词

作者简介

Ol'ga Vinogradova

Anna Turkina

Aleksandra Vorontsova

Ekaterina Chelysheva

Galina Gusarova

S Kuznetsov

Svetlana Goryacheva

Manana Sokolova

Evgeniy Abakumov

Ol'ga Stakhina

Elena Domracheva

Andrey Misyurin

Nina Khoroshko

O Vinogradova

A Turkina

A Vorontsova

E Chelysheva

G Gusarova

S Kuznetsov

S Goryacheva

M Sokolova

E Abakumov

O Stakhina

E Domracheva

A Misyurin

N Khoroshko

参考

补充文件